Celebrity Magic Johnson Teams with OraSure (OSUR) to Launch In-Home HIV Test
Get Alerts OSUR Hot Sheet
Price: $3.84 -4.48%
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
9 Buy, 8 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
OraSure Technologies (Nasdaq: OSUR) has hired celebrity Magic Johnson as spokesperson for its In-Home HIV Test, according analysts at Canaccord Genuity. The product is now for sale at over 30,000 retailers and online across the U.S.
"Our channel checks indicate the product is widely available," said analyst Jeffrey Frelick.
Frelick thinks Magic Johnson is an excellent choice given his stature as the face of HIV.
Canaccord Genuity has a Buy rating on OraSure Technologies (NASDAQ: OSUR) with a price target of $14.00.
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $10.40 yesterday.
"Our channel checks indicate the product is widely available," said analyst Jeffrey Frelick.
Frelick thinks Magic Johnson is an excellent choice given his stature as the face of HIV.
Canaccord Genuity has a Buy rating on OraSure Technologies (NASDAQ: OSUR) with a price target of $14.00.
For an analyst ratings summary and ratings history on OraSure Technologies click here. For more ratings news on OraSure Technologies click here.
Shares of OraSure Technologies closed at $10.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Piper Sandler Reiterates Overweight Rating on Estee Lauder (EL), 'F4Q26 Preview'
- Powell Industries (POWL) PT Lowered to $235 at Cantor Fitzgerald
- KinderCare Learning Companies (KLC) PT Lowered to $4.50 at UBS
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Corporate NewsRelated Entities
Canaccord GenuitySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share